114.51
0.90 (0.79%)
| Previous Close | 113.61 |
| Open | 113.68 |
| Volume | 532,414 |
| Avg. Volume (3M) | 865,295 |
| Market Cap | 8,187,465,216 |
| Price / Earnings (TTM) | 11.82 |
| Price / Earnings (Forward) | 8.24 |
| Price / Sales | 0.620 |
| Price / Book | 21.63 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | 6.63% |
| Operating Margin (TTM) | 13.44% |
| Diluted EPS (TTM) | 10.08 |
| Quarterly Revenue Growth (YOY) | 5.00% |
| Quarterly Earnings Growth (YOY) | -32.00% |
| Total Debt/Equity (MRQ) | 742.20% |
| Current Ratio (MRQ) | 1.25 |
| Operating Cash Flow (TTM) | 2.34 B |
| Levered Free Cash Flow (TTM) | 1.58 B |
| Return on Assets (TTM) | 7.04% |
| Return on Equity (TTM) | 54.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Care Facilities (US) | Mixed | Mixed |
| Medical Care Facilities (Global) | Mixed | Mixed | |
| Stock | DaVita Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.63 |
|
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business. |
|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Investment Style | Mid Core |
| % Held by Insiders | 49.51% |
| % Held by Institutions | 48.76% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 143.00 (Barclays, 24.88%) | Hold |
| Median | 138.00 (20.51%) | |
| Low | 133.00 (TD Cowen, 16.15%) | Hold |
| Average | 138.00 (20.51%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 118.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 03 Nov 2025 | 133.00 (16.15%) | Hold | 119.05 |
| Barclays | 30 Oct 2025 | 143.00 (24.88%) | Hold | 118.75 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Dec 2025 | Announcement | DaVita Names New Leaders to Accelerate Care Transformation |
| 14 Nov 2025 | Announcement | DaVita Inc. to Participate in Fireside Chat with Wolfe Research |
| 04 Nov 2025 | Announcement | DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025 |
| 29 Oct 2025 | Announcement | DaVita Inc. 3rd Quarter 2025 Results |
| 20 Oct 2025 | Announcement | DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |